Get the Stockscreener App
31.73
35.24%
-17.27
After Hours:
32.28
0.55
+1.73%
Maze Therapeutics Inc stock is traded at $31.73, with a volume of 8.24M.
It is down -35.24% in the last 24 hours and down -32.82% over the past month.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
See More
Previous Close:
$49.00
Open:
$40
24h Volume:
8.24M
Relative Volume:
13.17
Market Cap:
$1.53B
Revenue:
$2.50M
Net Income/Loss:
$-86.49M
P/E Ratio:
-14.07
EPS:
-2.2544
Net Cash Flow:
-
1W Performance:
-34.54%
1M Performance:
-32.82%
6M Performance:
+20.42%
1Y Performance:
+172.83%
1-Day Range:
$29.77
$41.00
1-Week Range:
$29.77
$50.70
52-Week Range:
$6.71
$53.65
Maze Therapeutics Inc Stock (MAZE) Company Profile
Name
Maze Therapeutics Inc
Sector
Industry
Phone
(650) 850-5070
Address
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
31.73 | 2.36B | 2.50M | -86.49M | 0 | -2.2544 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Buy |
| Mar-10-26 | Initiated | Mizuho | Outperform |
| Dec-04-25 | Initiated | Wells Fargo | Overweight |
| Nov-14-25 | Initiated | Raymond James | Outperform |
| Sep-02-25 | Initiated | BTIG Research | Buy |
| Jul-23-25 | Initiated | H.C. Wainwright | Buy |
| Jul-08-25 | Initiated | Wedbush | Outperform |
View All
Maze Therapeutics Inc Stock (MAZE) Latest News
Maze Therapeutics' (MAZE) "Buy" Rating Reiterated at BTIG Research - MarketBeat
Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829 - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Mizuho reiterates Maze Therapeutics stock rating on phase 2 data By Investing.com - Investing.com Australia
Truist reiterates Buy on Maze Therapeutics stock after trial data By Investing.com - Investing.com Canada
Maze Therapeutics posts trial data for lead drug (MAZE:NASDAQ) - Seeking Alpha
HC Wainwright Raises Maze Therapeutics (NASDAQ:MAZE) Price Target to $110.00 - MarketBeat
Mizuho reiterates Maze Therapeutics stock rating on phase 2 data - Investing.com
Leerink reiterates Maze Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Why Maze Therapeutics Stock Is Sinking After Good News - TipRanks
Maze Therapeutics stock soars 22% on positive trial data for MZE829 - Investing.com
Maze Therapeutics adds Neil Kumar to board leadership - TipRanks
Earnings Flash (MAZE) Maze Therapeutics Posts Q4 Net Loss $0.65 a Share, vs. FactSet Est of $0.72 Loss - marketscreener.com
Maze Therapeutics 2025 10-K: Revenue $0M, EPS $(3.05) - TradingView
Maze appoints Neil Kumar to its board as Class I director - TradingView
Maze Therapeutics Inc. unveils encouraging results for MZE829 APOL1 inhibitor in AMKD patients - Traders Union
Maze Therapeutics reports bigger-than-expected Q4 loss on higher R&D costs - TradingView
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease - The Manila Times
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights - Bluefield Daily Telegraph
Maze Therapeutics Announces Positive Topline Data from - GlobeNewswire
Portfolio Shifts: What analysts say about Maze Therapeutics Inc stockFed Meeting & AI Driven Price Forecasts - baoquankhu1.vn
This Evommune analyst begins coverage on a bullish note; here are top 5 initiations for Wednesday - MSN
This strategy analyst begins coverage on a bullish note; here are top 5 initiations for Tuesday - MSN
Maze Therapeutics (MAZE) Executive Stock Sale & 2026 Company PerformanceNews and Statistics - IndexBox
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears - Yahoo Finance
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears - The Motley Fool
Harold Bernstein Sells 15,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - MarketBeat
Maze Therapeutics president Bernstein sells $736k in stock By Investing.com - Investing.com Canada
Maze Therapeutics (NASDAQ:MAZE) Upgraded to "Strong-Buy" at Truist Financial - MarketBeat
Truist Securities initiates coverage of Maze Therapeutics (MAZE) with buy recommendation - MSN
Fundamentals Check: What analysts say about Maze Therapeutics Inc stockEarnings Growth Summary & Weekly High Potential Stock Alerts - baoquankhu1.vn
Wells Fargo initiates coverage of Maze Therapeutics (MAZE) with overweight recommendation - MSN
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Truist initiates Maze Therapeutics stock coverage with buy rating By Investing.com - Investing.com Canada
Maze Therapeutics (NASDAQ:MAZE) Sets New 1-Year High After Analyst Upgrade - Defense World
Maze Therapeutics (NASDAQ:MAZE) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat
Foresite Capital Management IV LLC Sells 1,589,262 Shares of Maze Therapeutics, Inc. $MAZE - MarketBeat
Foresite Capital Management V LLC Sells 258,900 Shares of Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics, Inc. News — NASDAQ:MAZE - TradingView
Boothbay Fund Management LLC Acquires 276,345 Shares of Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
545,132 Shares in Maze Therapeutics, Inc. $MAZE Acquired by ArrowMark Colorado Holdings LLC - MarketBeat
Maze Therapeutics stock hits all-time high at 49.28 USD By Investing.com - Investing.com Nigeria
Maze Therapeutics (NASDAQ:MAZE) Upgraded at Mizuho - Defense World
Assessing Maze Therapeutics (MAZE) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Maze Therapeutics (NASDAQ:MAZE) Rating Increased to Strong-Buy at Mizuho - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) CMO Sells 30,000 Shares - MarketBeat
Maze Therapeutics Executive Sells All Common Stock Holdings - TradingView
Maze Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Maze Therapeutics stock hits all-time high at 49.28 USD - Investing.com Australia
Maze Therapeutics (NASDAQ:MAZE) Sets New 12-Month HighShould You Buy? - MarketBeat
Maze Therapeutics Inc Stock (MAZE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Maze Therapeutics Inc Stock (MAZE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bernstein Harold | President, R&D & CMO |
Mar 20 '26 |
Sale |
49.10 |
15,000 |
736,439 |
0 |
| Bernstein Harold | President, R&D & CMO |
Mar 10 '26 |
Option Exercise |
10.42 |
30,000 |
312,600 |
30,000 |
| Bernstein Harold | President, R&D & CMO |
Mar 10 '26 |
Sale |
50.45 |
30,000 |
1,513,560 |
0 |
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):